Chemical and radiochemical considerations in radiolabeling with α-emitting radionuclides

Current Radiopharmaceuticals

Volumn 4, Issue 3, 2011, Pages 214-247

  Wilbur, D Scott ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Actinium 225; Alpha emitter; Astatine 211; Bismuth 212; Bismuth 213; Chelate; Fermium 255; Radioimmunotherapy; Radiolabeling; Radium 223; Radium 224; Targeted alpha radiotherapy; Terbium 149; Thorium 226; Thorium 227

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID AC 225; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAKIS(METHYLENEPHOSPHONIC ACID); ACTINIUM 225; ASTATINE 211; BISMUTH 212; BISMUTH 213; BORON DERIVATIVE; CHELATING AGENT; EDETIC ACID DERIVATIVE; FERMIUM 255; FULLERENE DERIVATIVE; LANTHANIDE; LIPOSOME; MONOCLONAL ANTIBODY; NANOPARTICLE; PENTETATE INDIUM IN 111; PENTETIC ACID DERIVATIVE; POLYMER; RADIOISOTOPE; RADIOPHARMACEUTICAL AGENT; RADIUM 223; RADIUM 224; SINGLE WALLED NANOTUBE; TERBIUM 149; THORIUM 226; THORIUM 227; UNCLASSIFIED DRUG;

CHELATION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG STABILITY; HEMATOPOIETIC CELL; ISOTOPE LABELING; NEUTRON CAPTURE THERAPY; NONHUMAN; OXIDATION; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; RADIOIODINATION; REVIEW; THERMODYNAMICS;

EID: 79959556136     PISSN: 18744710     EISSN: 18744729     Source Type: Journal    
DOI: 10.2174/1874471011104030214     Document Type: Review

References (329)

1. Kassis, A.I.; Adelstein, S.J. Radiobiologic principles in radionuclide therapy. J. Nucl. Med., 2005, 46 Suppl. 1, 4S-12S.
2. Vaidyanathan, G.; Zalutsky, M.R. Targeted therapy using alpha emitters. Phys. Med. Biol., 1996, 41, 1915-1931.
3. McDevitt, M.R.; Sgouros, G.; Finn, R.D.; Humm, J.L.; Jurcic, J.G.; Larson, S.M.; Scheinberg, D.A. Radioimmunotherapy with alphaemitting nuclides. Eur. J. Nucl. Med., 1998, 25, 1341-1351.
4. Allen, B.J. Targeted alpha therapy: Evidence for potential efficacy of alpha-immunoconjugates in the management of micrometastatic cancer. Australas Radiol., 1999, 43, 480-486.
5. Imam, S.K. Advancements in cancer therapy with alpha-emitters: A review. Int. J. Rad. Oncol. Biol. Phys., 2001, 51, 271-278.
6. Allen, B.J.; Raja, C.; Rizvi, S.; Li, Y.; Tsui, W.; Zhang, D.; Song, E.; Qu, C.F.; Kearsley, J.; Graham, P.; Thompson, J. Targeted alpha therapy for cancer. Phys. Med. Biol., 2004, 49, 3703-3712.
7. Mulford, D.A.; Scheinberg, D.A.; Jurcic, J.G. The promise of targeted alpha-particle therapy. J. Nucl. Med., 2005, 46 Suppl. 1, 199S-204S.
8. Couturier, O.; Supiot, S.; Degraef-Mougin, M.; Faivre-Chauvet, A.; Carlier, T.; Chatal, J.F.; Davodeau, F.; Cherel, M. Cancer radioimmunotherapy with alpha-emitting nuclides. Eur. J. Nucl. Med. Mol. Imaging, 2005, 32, 601-614.
9. Brechbiel, M.W. Targeted alpha-therapy: Past, present, future? Dalton Trans., 2007, 4918-4928.
10. Dadachova, E. Cancer therapy with alpha-emitters labeled peptides. Semin. Nucl. Med., 2010, 40, 204-8.
11. Miederer, M.; Scheinberg, D.A.; McDevitt, M.R. Realizing the potential of the actinium-225 radionuclide generator in targeted alpha particle therapy applications. Adv. Drug Deliv. Rev., 2008, 60, 1371-1382.
12. Goldenberg, D.M. Targeted therapy of cancer with radiolabeled antibodies. J. Nucl. Med., 2002, 43, 693-713.
13. Adams, G.P.; Weiner, L.M. Monoclonal antibody therapy of cancer. Nat. Biotechnol., 2005, 23, 1147-1157.
14. Stern, M.; Herrmann, R. Overview of monoclonal antibodies in cancer therapy: Present and promise. Crit. Rev. Oncol. Hematol., 2005, 54, 11-29.
15. Sharkey, R.M.; Goldenberg, D.M. Targeted therapy of cancer: New prospects for antibodies and immunoconjugates. CA Cancer J. Clin., 2006, 56, 226-243.
16. Meares, C.F. Chelating agents for the binding of metal ions to antibodies. Nucl. Med. Biol., 1986, 13, 311-318.
17. Gansow, O.A. Newer approaches to the radiolabeling of monoclonal antibodies by use of metal chelates. Nucl. Med. Biol., 1991, 18, 369-381.
18. Kaden, T.A. Labelling monoclonal antibodies with macrocyclic radiometal complexes. A challenge for coordination chemists. Dalton Trans., 2006, 3617-23.
19. Sosabowski, J.; Melendez-Alafort, L.; Mather, S. Radiolabeling of peptides for diagnosis and therapy of non-oncological diseases. Q. J. Nucl. Med., 2003, 47, 223-237.
20. Fichna, J.; Janecka, A. Synthesis of target-specific radiolabeled peptides for diagnostic imaging. Bioconjugate Chem., 2003, 14, 3-17.
21. Reubi, J.C.; Macke, H.R.; Krenning, E.P. Candidates for peptide receptor radiotherapy today and in the future. J. Nucl. Med., 2005, 46 Suppl. 1, 67S-75S.
22. Weiner, R.E.; Thakur, M.L. Radiolabeled peptides in oncology: Role in diagnosis and treatment. BioDrugs, 2005, 19, 145-63.
23. Forrer, F.; Valkema, R.; Kwekkeboom, D.J.; de Jong, M.; Krenning, E.P. Neuroendocrine tumors. Peptide receptor radionuclide therapy. Best Pract. Res. Clin. Endocrinol. Metab., 2007, 21, 111-129.
24. Okarvi, S.M. Peptide-based radiopharmaceuticals and cytotoxic conjugates: Potential tools against cancer. Cancer Treat. Rev., 2008, 34, 13-26.
25. 131I]MIBG). Nucl. Med. Biol., 1987, 14, 183-189.
26. Jaggi, J.S.; Kappel, B.J.; McDevitt, M.R.; Sgouros, G.; Flombaum, C.D.; Cabassa, C.; Scheinberg, D.A. Efforts to control the errant products of a targeted in vivo generator. Cancer Res., 2005, 65, 4888-4895.
27. Jaggi, J.S.; Seshan, S.V.; McDevitt, M.R.; Sgouros, G.; Hyjek, E.; Scheinberg, D.A. Mitigation of radiation nephropathy after internal alpha-particle irradiation of kidneys. Int. J. Radiat. Oncol. Biol. Phys., 2006, 64, 1503-1512.
28. Pingree, S.D.; Simmonds, P.L.; Woods, J.S. Effects of 2,3-dimercapto-1-propanesulfonic acid (DMPS) on tissue and urine mercury levels following prolonged methylmercury exposure in rats. Toxicol. Sci., 2001, 61, 224-233.
29. Park, S.I.; Shenoi, J.; Pagel, J.M.; Hamlin, D.K.; Wilbur, D.S.; Orgun, N.; Kenoyer, A.L.; Frayo, S.; Axtman, A.; Back, T.; Lin, Y.; Fisher, D.R.; Gopal, A.K.; Green, D.J.; Press, O.W. Conventional and pretargeted radioimmunotherapy using bismuth-213 to target and treat non-hodgkin lymphomas expressing CD20: A preclinical model toward optimal consolidation therapy to eradicate minimal residual disease. Blood, 2010, 116, 4231-4239.
30. Nilsson, S.; Larsen, R.H.; Fossa, S.D.; Balteskard, L.; Borch, K.W.; Westlin, J.E.; Salberg, G.; Bruland, O.S. First clinical experience with alpha-emitting radium-223 in the treatment of skeletal metastases. Clin. Cancer Res., 2005, 11, 4451-4459.
31. th ed.; John Wiley & Sons: New York, 1980.
32. Vasáros, L.; Berei, K., General properties of astatine. In Gmelin handbook of inorganic chemistry. Astatine, 8th ed.; Kugler, H. K.; Keller, C., Eds. Springer-Verlag: Berlin, 1985, pp. 107-128.
33. Gregus, Z.; Klaassen, C.D. Disposition of metals in rats: A comparative study of fecal, urinary, and biliary excretion and tissue distribution of eighteen metals. Toxicol. Appl. Pharmacol., 1986, 85, 24-38.
34. 206Bi in the normal rat. Radiat. Res., 1975, 63, 443-54.
35. Zidenberg-Cherr, S.; Parks, N.J.; Keen, C.L. Tissue and subcellular distribution of bismuth radiotracer in the rat: Considerations of cytotoxicity and microdosimetry for bismuth radiopharmaceuticals. Radiat. Res., 1987, 111, 119-129.
36. Milenic, D.E.; Roselli, M.; Brechbiel, M.W.; Pippin, C.G.; McMurray, T.J.; Carrasquillo, J.A.; Colcher, D.; Lambrecht, R.; Gansow, O.A.; Schlom, J. In vivo evaluation of a lead-labeled monoclonal antibody using the DOTA ligand. Eur. J. Nucl. Med., 1998, 25, 471-480.
37. Ando, A.; Ando, I.; Hiraki, T.; Hisada, K. Relation between the location of elements in the periodic table and various organ-uptake rates. Nucl. Med. Biol., 1989, 16, 57-80.
38. 89Sr in mice. J. Nucl. Med., 2003, 44, 252-259.
39. 211 (eka-iodine) in the thyroid gland of rats and monkeys. J. Clin. Endocrinol. Metab., 1954, 14, 1161-1178.
40. 211At]astatide and development of labeling reagents to increase stability. Curr. Radiopharm., 2008, 1, 144-176.
41. Liu, S.; Edwards, D.S. Bifunctional chelators for therapeutic lanthanide radiopharmaceuticals. Bioconj. Chem., 2001, 12, 7-34.
42. Schubiger, P.A.; Alberto, R.; Smith, A. Vehicles, chelators, and radionuclides: Choosing the "building blocks" of an effective therapeutic radioimmunoconjugate. Bioconj. Chem., 1996, 7, 165-179.
43. Heeg, M.J.; Jurisson, S.S. The role of inorganic chemistry in the development of radiometal agents for cancer therapy. Acc. Chem. Res., 1999, 32, 1053-1060.
44. Volkert, W.A.; Goeckeler, W.F.; Ehrhardt, G.J.; Ketring, A.R. Therapeutic radionuclides: Production and decay property considerations. J. Nucl. Med., 1991, 32, 174-185.
45. Liu, S. The role of coordination chemistry in the development of target-specific radiopharmaceuticals. Chem. Soc. Rev., 2004, 33, 445-461.
46. Yuanfang, L.; Chuanchu, W. Radiolabeling of monoclonal antibodies with metal chelates. Pure Appl. Chem., 1991, 363, 427-463.
47. 213Bi, and their decay chain related radionuclides, for therapeutic applications. Chem. Rev., 2001, 101, 2019-2036.
48. Cooper, M.S.; Sabbah, E.; Mather, S.J. Conjugation of chelating agents to proteins and radiolabeling with trivalent metallic isotopes. Nat. Protoc., 2006, 1, 314-317.
49. Caravan, P.; Ellison, J.J.; McMurry, T.J.; Lauffer, R.B. Gadolinium(III) chelates as MRI contrast agents: Structure, dynamics, and applications. Chem. Rev., 1999, 99, 2293-2352.
50. Meares, C.F.; Wensel, T.G. Metal chelates as probes of biological systems. Acc. Chem. Res., 1984, 17, 202-209.
51. Meares, C.F.; McCall, M.J.; Reardan, D.T.; Goodwin, D.A.; Diamanti, C.I.; McTigue, M. Conjugation of antibodies with bifunctional chelating agents: Isothiocyanate and bromoacetamide reagents, methods of analysis, and subsequent addition of metal ions. Anal. Biochem., 1984, 142 (1), 68-78.
52. Brechbiel, M.W.; Gansow, O.A.; Atcher, R.W.; Schlom, J.; Esteban, J.; Simpson, D.E.; Colcher, D. Synthesis of 1-(pisothiocyanatobenzyl) derivatives of DTPA and EDTA. Antibody labeling and tumor imaging. Inorg. Chem., 1986, 25, 2772-2781.
53. DeRiemer, L.H.; Meares, C.F.; Goodwin, D.A.; Diamanti, C.I. Synthesis of a new tumor-visualizing derivative of Co(III)-bleomycin. J. Labelled Compd. Radiopharm., 1981, 18, 1517-1534.
54. Westerberg, D.A.; Carney, P.L.; Rogers, P.E.; Kline, S.J.; Johnson, D.K. Synthesis of novel bifunctional chelators and their use in preparing monoclonal antibody conjugates for tumor targeting. J. Med. Chem., 1989, 32, 236-243.
55. Subramanian, R.; Colony, J.; Shaban, S.; Sidrak, H.; Haspel, M.V.; Pomato, N.; Hanna, M.G.; McCabe, R.P. New chelating agent for attaching indium-111 to monoclonal antibodies: In vitro and in vivo evaluation. Bioconj. Chem., 1992, 3, 248-255.
56. Arslantas, E.; Smith-Jones, P.M.; Ritter, G.; Schmidt, R.R. Tame-Hex A-a novel bifunctional chelating agent for radioimmunoimaging. Eur. J. Org. Chem., 2004, 3979-3984.
57. Margerum, D.W.; Cayley, G.R.; Weatherburn, D.C.; Pagenkopf, G.K., Kinetics and mechanisms of complex formation and ligand exchange. In Coordination Chemistry, Monograph 174, Martell, A.E., Ed. American Chemical Society: Washington, D.C., 1978, Vol. 2.
58. 90Y radioimmunotherapy. Bioconj. Chem., 1991, 2, 187-194.
59. Mirzadeh, S. Radiometal labeling of immunoproteins: Covalent linkage of 2-(4-isothiocyanatobenzyl)diethylenetriaminepentaacetic acid ligands to immunoglobulin. Bioconj. Chem., 1990, 1, 59-65.
60. Cummins, C.H.; Rutter, E.W., Jr.; Fordyce, W.A. A convenient synthesis of bifunctional chelating agents based on diethylenetriaminepentaacetic acid and their coordination chemistry with yttrium(III). Bioconj. Chem., 1991, 2 (3), 180-186.
61. Camera, L.; Kinuya, S.; Garmestani, K.; Brechbiel, M.W.; Wu, C.; Pai, L.H.; McMurry, T.J.; Gansow, O.A.; Pastan, I.; Paik, C.H.; Carrasquillo, J.A. Comparative biodistribution of indium-and yttrium-labeled B3 monoclonal antibody conjugated to either 2-(p-SCN-Bz)-6-methyl-DTPA (1B4M-DTPA) or 2-(p-SCN-Bz)-1,4,7,10-tetraazacyclododecane tetraacetic acid (2B-DOTA). Eur. J. Nucl. Med., 1994, 21, 640-646.
62. Hamm, R.E.; Suwyn, M.A. Preparation and characterization of some aminopolycarboxylate complexes of manganese(III). Inorg. Chem., 1967, 6, 139-142.
63. Carr, J.D.; Libby, R.A.; Margerum, D.W. Multidentate ligand kinetics. Xi. Polyamine reactions with copper complexes of ethylenediaminetetraacetate and cyclohexylene-diaminetetraacetate ions. Inorg. Chem., 1967, 6, 1083-1088.
64. de Sousa, A.S.; Graeme, J.B.; Croft, C.A.; Michael, J.P.; Hancock, R.D. Effect of cyclohexylene bridges on the metal ion size based selectivity of ligands in aqueous solution. Inorg. Chem., 1991, 30, 3525-3529.
65. 212Bi for B-particle mediated radioimmunotherapy. J. Chem. Soc., Chem. Commun., 1991, 1169-1170.
66. Brechbiel, M.W.; Gansow, O.A. Synthesis of c-functionalized trans-cyclohexyldiethylenetriamine-penta-acetic acids for labelling of monoclonal antibodies with the bismuth-212 o-particle emitter. J. Chem. Soc. Perkin Trans. 1, 1992, 1173-1178.
67. Kobayashi, H.; Wu, C.C.; Yoo, T.M.; Sun, B.F.; Drumm, D.; Pastan, I.; Paik, C.H.; Gansow, O.A.; Carrasquillo, J.A.; Brechbiel, M.W. Evaluation of the in vivo biodistribution of yttrium-labeled isomers of CHX-DTPA-conjugated monoclonal antibodies. J. Nucl. Med., 1998, 39, 829-836.
68. McMurry, T.J.; Pippin, C.G.; Wu, C.C.; Deal, K.A.; Brechbiel, M.W.; Mirzadeh, S.; Gansow, O.A. Physical parameters and biological stability of yttrium(III) diethylenetriaminepentaacetic acid derivative conjugates. J. Med. Chem., 1998, 41, 3546-3549.
69. Chong, H.-S.; Garmestani, K.; Bryant, L.H., Jr.; Milenic, D.E.; Overstreet, T.; Birch, N.; Le, T.; Brady, E.D.; Brechbiel, M.W. Synthesis and evaluation of novel macrocyclic and acyclic ligands as contrast enhancement agents for magnetic resonance imaging. J. Med. Chem., 2006, 49, 2055-2062.
70. Chong, H.S.; Milenic, D.E.; Garmestani, K.; Brady, E.D.; Arora, H.; Pfiester, C.; Brechbiel, M.W. In vitro and in vivo evaluation of novel ligands for radioimmunotherapy. Nucl. Med. Biol., 2006, 33 (4), 459-467.
71. Pickersgill, I.F.; Rapoport, H. Preparation of functionalized, conformationally constrained DTPA analogues from l-or d-serine and trans-4-hydroxy-l-proline. Hydroxymethyl substituents on the central acetic acid and on the backbone. J. Org. Chem., 2000, 65, 4048-57.
72. Voloshin, Y.Z.; Varzatskii, O.A.; Bubnov, Y.N. Cage complexes of transition metals in biochemistry and medicine. Russ. Chem. Bull., Int. Ed., 2007, 56, 577-605.
73. Loncin, M.F.; Desreux, J.F.; Merciny, E. Coordination of lanthanides by two polyamino polycarboxylic macrocycles: Formation of highly stable lanthanide complexes. Inorg. Chem., 1986, 25, 2646-2648.
74. Cacheris, W.P.; Nickle, S.K.; Sherry, A.D. Thermodynamic study of lanthanide complexes of 1,4,7-triazacyclononane-N, Ń, Ń́-triacetic acid and 1,4,7,10-tetraazacyclododecane-N, Ń, Ń́, Ń́́-tetraacetic acid. Inorg. Chem., 1987, 26, 958-960.
75. Toth, E.; Brucher, E. Stability constants of the lanthanide(III)-1,4,7,10-tetraazacyclododecane-N, Ń, Ń́, Ń́́-tetraacetate complexes. Inorganica Chimica Acta, 1994, 221, 165-167.
76. 149Tb for medical application. Radiochim. Acta, 2002, 90, 247-252.
77. 152. Phys. Rev., 1959, 115, 158-159.
78. Allen, B.J.; Goozee, G.; Sarkar, S.; Beyer, G.; Morel, C.; Byrne, A.P. Production of terbium-152 by heavy ion reactions and proton induced spallation. Appl. Radiat. Isot., 2001, 54, 53-58.
79. Miederer, M.; Seidl, C.; Beyer, G.-J.; Charlton, D.E.; Vranjes-Duric, S.; Comor, J.J.; Huber, R.; Nikula, T.; Apostolidis, C.; Schuhmacher, C.; Becker, K.-F.; Senekowitsch-Schmidtke, R. Comparison of the radiotoxicity of 2 alpha-particle-emitting immunoconjugates, terbium-149 and bismuth-213, directed against a tumor-specific, exon 9 deleted (d9) e-cadherin adhesion protein. Radiat. Res., 2003, 159, 612-620.
80. 149Tb-rituximab. Eur. J. Nucl. Med. Mol. Imaging, 2004, 31, 547-54.
81. Kozak, R.W.; Atcher, R.W.; Gansow, O.A.; Friedman, A.M.; Hines, J.J.; Waldmann, T.A. Bismuth-212-labeled anti-tac monoclonal antibody: m-particle-emitting radionuclides as modalities for radioimmunotherapy. Proc. Natl. Acad. Sci. USA, 1986, 83, 474-478.
82. 212bismuth linked to an antipancreatic carcinoma antibody: Model for alpha-particleemitter radioimmunotherapy. J. Nucl. Cancer Inst., 1988, 80, 449-452.
83. Macklis, R.M.; Kinsey, B.M.; Kassis, A.I.; Ferrara, J.L.M.; Atcher, R.W.; Hines, J.J.; Coleman, C.N.; Adelstein, S.J.; Burakoff, S.J. Radioimmuno-therapy with alpha-particle-emitting immunoconjugates. Science, 1988, 240, 1024-1026.
84. Macklis, R.M.; Kaplan, W.D.; Ferrara, J.L.M.; Atcher, R.W.; Hines, J.J.; Burakoff, S.J.; Coleman, C.N. Alpha particle radioimmunotherapy: Animal models and clinical prospects. Int. J. Rad. Oncol. Biol. Phys., 1989, 16, 1377-1387.
85. 212bismuth, chelated to a monoclonal antibody. Anti. Immuno. Radiopharm., 1988, 1, 43-53.
86. 90Y-labeled CO17-1a Fab' fragments in a human colonic cancer model. Cancer Res., 1999, 59, 2635-2643.
87. Ruegg, C.L.; Anderson-Berg, W.T.; Brechbiel, M.W.; Mirzadeh, S.; Gansow, O.A.; Strand, M. Improved in vivo stability and tumor targeting of bismuth-labeled antibody. Cancer Res., 1990, 50, 4221-4226.
88. Rizvi, S.M.A.; Sarkar, S.; Goozee, G.; Allen, B.J. Radioimmunoconjugates for targeted a therapy of malignant melanoma. Melanoma Res., 2000, 10, 281-289.
89. Song, E.Y.; Abbas Rizvi, S.M.; Qu, C.F.; Raja, C.; Brechbiel, M.W.; Morgenstern, A.; Apostolidis, C.; Allen, B.J. Pharmacokinetics and toxicity of (213)Bi-labeled pai2 in preclinical targeted alpha therapy for cancer. Cancer Biol. Ther., 2007, 6, 898-904.
90. Allen, B.J.; Rizvi, S.M.; Tian, Z. Preclinical targeted alpha therapy for subcutaneous melanoma. Melanoma Res., 2001, 11, 175-82.
91. Ranson, M.; Tian, Z.; Andronicos, N.M.; Rizvi, S.; Allen, B.J. In vitro cytotoxicity of bismuth-213 (213bi)-labeled-plasminogen activator inhibitor type 2 (alpha-pai-2) on human breast cancer cells. Breast Cancer Res. Treat., 2002, 71, 149-59.
92. Li, Y.; Tian, Z.; Rizvi, S.M.; Bander, N.H.; Allen, B.J. In vitro and preclinical targeted alpha therapy of human prostate cancer with Bi-213 labeled J591 antibody against the prostate specific membrane antigen. Prostate Cancer Prostatic Dis., 2002, 5, 36-46.
93. Allen, B.J.; Raja, C.; Rizvi, S.; Li, Y.; Tsui, W.; Graham, P.; Thompson, J.F.; Reisfeld, R.A.; Kearsley, J. Intralesional targeted alpha therapy for metastatic melanoma. Cancer Biol. Ther., 2005, 4 (12), 1318-1324.
94. 213Bi labeled pai2 for the control of micrometastatic pancreatic cancer. Clin. Exp. Metastasis, 2005, 22, 575-86.
95. 213Bi-labeled multiple targeted alpha radioimmuno-conjugates. Prostate, 2006, 66, 1753-67.
96. 213Bi-labeled plasminogen activator inhibitor type 2 in an orthotopic murine xenogenic model of human breast carcinoma. Mol. Cancer Ther., 2007, 6, 203-212.
97. 213Bi-herceptin radioimmunoconjugate. Cancer Lett., 2005, 218, 181-90.
98. Tiffany, L.J.; Dobbs, D.; Garmestani, K.; Raubitschek, A.; Tinubu, A.; Brechbiel, M.W.; Goffman, T.; Gansow, O.A.; Waldmann, T.A.; Kozak, R.W. Radiolabeled CHXB-2E4 is stable in vivo and is a suitable immunoconjugate for testing l-particle-emitting bismuth radionuclides in interleukin-2 receptor targeted immunotherapy. Anti. Immuno. Radiopharm., 1994, 7, 99-115.
99. 213Bi. Br. J. Cancer, 1999, 80, 175-184.
100. Milenic, D.E.; Roselli, M.; Mirzadeh, S.; Pippin, C.G.; Gansow, O.A.; Colcher, D.; Brechbiel, M.W.; Schlom, J. In vivo evaluation of bismuth-labeled monoclonal antibody comparing DTPA-derived bifunctional chelates. Cancer Biother. Radiopharm., 2001, 16, 133-146.
101. 213Bi]J591) for radioimmunotherapy of prostate cancer. Cancer Res., 2000, 60, 6095-6100.
102. Huneke, R.B.; Pippin, C.G.; Squire, R.A.; Brechbiel, M.W.; Gansow, O.A.; Strand, M. Effective G-paricle-mediated radioimmunotherapy of murine leukemia. Cancer Res., 1992, 52, 5818-5820.
103. 212Bi-anti-tac. Cancer Res., 1994, 54, 4362-4370.
104. Kennel, S.J.; Lankford, T.K.; Foote, L.J.; Davis, I.A.; Boll, R.A.; Mirzadeh, S. Combination vascular targeted and tumor targeted radioimmunotherapy. Cancer Biother. Radiopharm. 1999, 14, 371-379.
105. 213Bi-labeled antibody constructs for clinical use. J. Nucl. Med., 1999, 40, 1722-1727.
106. Nikula, T.K.; McDevitt, M.R.; Finn, R.D.; Wu, C.; Kozak, R.W.; Garmestani, K.; Brechbiel, M.W.; Curcio, M.J.; Pippin, C.G.; Tiffany-Jones, L.; Geerlings, M.W., Sr.; Apostolidis, C.; Molinet, R.; Geerlings, M.W., Jr.; Gansow, O.A.; Scheinberg, D.A. Alphaemitting bismuth cyclohexylbenzyl DTPA constructs of recombinant humanized anti-CD33 antibodies: Pharmacokinetics, bioactivity, toxicity and chemistry. J. Nucl. Med., 1999, 40, 166-176.
107. Ma, D.; McDevitt, M.R.; Finn, R.D.; Scheinberg, D.A. Rapid preparation of short-lived alpha particle emitting radioimmunopharmaceuticals. Appl. Radiat. Isot., 2001, 55, 463-470.
108. 213Bi-labeled monoclonal antibody against mutant e-cadherin suggests its usefulness for locoregional l-radioimmunotherapy of diffuse-type gastric cancer. Cancer Res., 2001, 61, 2804-2808.
109. 213Bi]-MAb TES-23. Eur. J. Cancer, 2002, 38, 1278-87.
110. Jurcic, J.G.; Larson, S.M.; Sgouros, G.; McDevitt, M.R.; Finn, R.D.; Divgi, C.R.; Ballangrud, A.M.; Hamacher, K.A.; Ma, D.; Humm, J.L.; Brechbiel, M.W.; Molinet, R.; Scheinberg, D.A. Targeted TTparticle immunotherapy for myeloid leukemia. Blood, 2002, 100, 1233-1239.
111. 213Bi-labeled anti-CD74. Nucl. Med. Bio., 2003, 30, 715-723.
112. 213Bi-labeled domaindeleted humanized monoclonal antibody. Cancer Biother. Radiopharm., 2004, 19 (2), 135-147.
113. Dadachova, E.; Howell, R.W.; Bryan, R.A.; Frenkel, A.; Nosanchuk, J.D.; Casadevall, A. Susceptibility of the human pathogenic fungi cryptococcus neoformans and histoplasma capsulatum to gamma-radiation versus radioimmunotherapy with alpha-and beta-emitting radioisotopes. J. Nucl. Med., 2004, 45, 313-320.
114. 213Bi-immunoconjugates in HSC45-M2 gastric cancer cells is different from apoptotic cell death. Eur. J. Nucl. Med. Mol. Imaging, 2005, 32, 274-285.
115. 213Bi-CHX-A"-C595. Cancer Biol. Ther., 2005, 4, 848-53.
116. 213Bi-C-functionalized trans-cyclohexyl-diethylenetriaminepentaacetic acid-humanized 3S193 is enhanced by combination with paclitaxel chemotherapy. Clin. Cancer Res., 2007, 13 (18 Pt 2), 5604s-5612s.
117. 213Biradioimmunotherapy using bioluminescence imaging. Eur. J. Nucl. Med. Mol. Imaging, 2007, 34, 841-849.
118. 213Bi-anti-EGFR-MAb defeats human bladder carcinoma in xenografted nude mice. J. Nucl. Med., 2009, 50, 1700-8.
119. Seidl, C.; Port, M.; Apostolidis, C.; Bruchertseifer, F.; Schwaiger, M.; Senekowitsch-Schmidtke, R.; Abend, M. Differential gene expression triggered by highly cytotoxic alpha-emitter-immunoconjugates in gastric cancer cells. Invest. New Drugs, 2010, 28, 49-60.
120. Sandmaier, B.M.; Bethge, W.A.; Wilbur, D.S.; Hamlin, D.K.; Santos, E.B.; Brechbiel, M.W.; Fisher, D.R.; Storb, R. Bismuth 213-labeled anti-CD45 radioimmunoconjugate to condition dogs for nonmyeloablative allogeneic marrow grafts. Blood, 2002, 100, 318-26.
121. Bethge, W.A.; Wilbur, D.S.; Storb, R.; Hamlin, D.K.; Santos, E.B.; Brechbiel, M.W.; Fisher, D.R.; Sandmaier, B.M. Selective T-cell ablation with bismuth-213-labeled anti-TCRalphabeta as nonmyeloablative conditioning for allogeneic canine marrow transplantation. Blood, 2003, 101, 5068-5075.
122. Bethge, W.A.; Wilbur, D.S.; Storb, R.; Hamlin, D.K.; Santos, E.B.; Brechbiel, M.W.; Sandmaier, B.M. Radioimmunotherapy with bismuth-213 as conditioning for nonmyeloablative allogeneic hematopoietic cell transplantation in dogs: A dose deescalation study. Transplantation, 2004, 78, 352-359.
123. Nakamae, H.; Wilbur, D.S.; Hamlin, D.K.; Thakar, M.S.; Santos, E.B.; Fisher, D.R.; Kenoyer, A.L.; Pagel, J.M.; Press, O.W.; Storb, R.; Sandmaier, B.M. Biodistributions, myelosuppression, and toxicities in mice treated with an anti-CD45 antibody labeled with the alpha-emitting radionuclides bismuth-213 or astatine-211. Cancer Res., 2009, 69, 2408-2415.
124. 213bismuth-labeled anti-CD45 MAb as a novel nonmyeloablative conditioning for DLA-haplo-identical littermate hematopoietic transplantation. Transplantation, 2010, 89, 1336-40.
125. Henriksen, G.; Funderud, S.; Hoff, P. Bi-labelled antibody and Bilabelled streptavidin. Comparison of targeting efficacy of a lymphoma cell line in vitro. J. Labl. Compd. Radiopharm., 1997, 39, 1039-1046.
126. 211At. Bioconj. Chem., 2008, 19, 158-70.
127. Pathare, P.M.; Hamlin, D.K.; Wilbur, D.S.; Brechbiel, M.W.; Bray, L.A. Synthesis and radiolabeling of a biotin-CHX-B chelate for Bi-213. J. Labl. Compd. Radiopharm., 1998, 41 (7), 595-603.
128. Beyer, G.J.; Offord, R.E.; Kunzi, G.; Jones, R.M.L.; Ravin, U.; Aleksandrova, Y.; Werlen, R.C.; Macke, H.; Lindroos, M.; Jahn, S.; Tengblad, D. Biokinetics of monoclonal antibodies labeled with radio-lanthanides and 225-Ac in xenografted nude mice. J. Labl. Compd. Radiopharm., 1995, 37, 529-530.
129. 225actinium chelates: Tissue distribution and radiotoxicity. Nucl. Med. Biol., 1999, 26, 581-9.
130. Baybarz, R.D. Dissociation constants of the transplutonium element chelates of diethylene-pentaacetic acid (DTPA) and the application of DTPA chelates to solvent extraction separations of transplutionium elements from the lanthanide elements. J. Inorg. Nucl. Chem., 1965, 27, 1831-1839.
131. Izatt, R.M.; Bradshaw, J.S.; Nielsen, S.A.; Lamb, J.D.; Christensen, J.J. Thermodynamic and kinetic data for cation-macrocycle interaction. Chem. Rev., 1985, 85, 271-339.
132. Izatt, R.M.; Pawlak, K.; Bradshaw, J.S. Thermodyamic and kinetic data for macrocyclic interaction with cations and anions. Chem. Rev., 1991, 91, 1721-2085.
133. Stetter, H.; Frank, W. Complex formation with tetraazaalkane-N, Ń, Ń́, Ń́́-tetraacetic acids as a funtion of ring size. Angew. Chem. Int. Ed. Engl., 1976, 15, 686.
134. Moi, M.K.; Meares, C.F.; McCall, M.J.; Cole, W.C.; DeNardo, S.J. Copper chelates as probes of biological systems: Stable copper complexes with a macrocyclic bifunctional chelating agent. Anal. Biochem., 1985, 148, 249-53.
135. 57Co. Nucl. Med. Biol., 1986, 13, 363-368.
136. Cole, W.C.; DeNardo, S.J.; Meares, C.F.; McCall, M.J.; DeNardo, G.L.; Epstein, A.L.; O'Brian, H.A.; Moi, M.K. Comparative serum stability of radiochelates for antibody radiopharmaceuticals. J. Nucl. Med., 1987, 28, 83-90.
137. Deshpande, S.V.; DeNardo, S.J.; Meares, C.F.; McCall, M.J.; Adams, G.P.; Moi, M.K.; DeNardo, G.L. Copper-67-labeled monoclonal antibody lym-1, a potential radiopharmaceutical for cancer therapy: Labeling and biodistribution in Raji tumored mice. J. Nucl. Med., 1988, 29, 217-25.
138. Keire, D.A.; Jang, Y.H.; Li, L.; Dasgupta, S.; Goddard, W.A., III; Shively, J.E. Chelators for radioimmunotherapy: I. NMR and ab initio calculation studies on 1,4,7,10-tetra(carboxyethyl)-1,4,7,10-tetraazacyclododecane (DO4PR) and 1,4,7-tris(carboxymethyl)-10-(carboxyethyl)-1,4,7,10-tetraazacyclododeca ne (DO3A1PR). Inorg. Chem., 2001, 40, 4310-4318.
139. 2O, and its relevance to NMR studies of the conformational behavior of the lanthanide complexes formed by macrocyclic ligand dota. Inorg. Chem., 1984, 23, 359-363.
140. Spirlet, M.-R.; Rebizant, J.; Loncin, M.-F.; Desreux, J.F. Structural characteristics of a terbium(III) complex with 1,4,8,11-tetraazacyclo-tetradecane-1,4,8,11-tetraacetic acid. Lanthanide ions and the conformation of the 14-member macrocycles. Inorg. Chem., 1984, 23, 4278-4283.
141. Chang, C.A.; Fancesconi, L.C.; Malley, M.F.; Kumar, K.; Gougoutas, J.Z.; Tweedle, M.F. Synthesis, characterization, and crystal structures of M(DO3A) (M = Fe, Gd) and Na[M(DOTA)] (M = Fe, Y, Gd). Inorg. Chem., 1993, 332, 3501-3508.
142. Parker, D.; Pulukkody, K.; Smith, F.C.; Batsanov, A.; Howard, J.A.K. Structures of the yttrium complexes of 1,4,7,10-tetraazacyclododecane-N, Ń, Ń́, Ń́́-tetraacetic acid
143. Lincoln, S.F. Mechanistic studies of some macrocyclic complexes. Coordination Chem. Rev., 1997, 166, 255-289.
144. Aime, S.; Botta, M.; Ermondi, G. NMR study of solution structures and dynamics of lanthanide(III) complexes of DOTA. Inorg. Chem., 1992, 31, 4291-4299.
145. Marques, M.P.M.; Geraldes, C.F.G.C.; Sherry, A.D.; Merbach, A.E.; Powell, H.; Pubanz, D.; Aime, S.; Botta, M. NMR conformational study of the lanthanide(iii) complexes of DOTA in aqueous solution. J. Alloys Compounds, 1995, (225), 303-307.
146. 1H-NMR spectroscopy. Inorg. Chem., 1997, 36, 2059-2068.
147. Moi, M.K.; Meares, C.F.; DeNardo, S.J. The peptide way to macrocyclic bifunctional chelating agents: Synthesis of 2-(pnitrobenzyl)-1,4,7,10-tetraazacyclododecane-N, N', N", N"'-tetraacetic acid and study of its yttrium(III) complex. J. Am. Chem. Soc., 1988, 110, 6266-6267.
148. Lewis, M.R.; Kao, J.Y.; Anderson, A.-L.J.; Shively, J.E.; Raubitschek, A. An improved method for conjugating monoclonal antibodies with N-hydroxysulfosuccinimidyl DOTA. Bioconj. Chem., 2001, 12 (2), 320-324.
149. Cox, J.P.L.; Jankowski, K.J.; Kataky, R.; Parker, D.; Beeley, N.R.A.; Boyce, B.A.; Eaton, M.A.W.; Millar, K.; Millican, A.T.; Harrison, A.; Walker, C. Synthesis of a kinetically stable yttrium-90 labelled macrocycle-antibody conjugate. J. Chem. Soc. Chem. Commun., 1989, 797-798.
150. Cox, J.P.L.; Craig, A.S.; Helps, I.M.; Jankowski, K.J.; Parker, D.; Eaton, M.A.W.; Millican, A.T.; Millar, K.; Beeley, N.R.A.; Boyce, B.A. Synthesis of C-and N-functionalized derivatives of 1,4,7-triazacyclononane-1,4,7-triylacetic acid (NOTA), 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetrayl-tetra-acetic acid (DOTA), and diethylene-triaminepenta-acetic acid (DTPA): Bifunctional complexing agents for the derivatisation of antibodies. J. Chem. Soc. Perkin Trans. I, 1990, 2567-2576.
151. Lewis, M.R.; Shively, J.E. Maleimidocysteine-amido-DOTA derivatives: New reagents for radiometal chelate conjugation to antibody sulfhydryl groups undergo pH-dependent cleavage reactions. Bioconj. Chem., 1998, 9, 72-86.
152. 90Y-labeled DOTA and maleimidocysteineamido-DOTA conjugated to chimeric anticarcinoembryonic antigen antibody in xenograft-bearing nude mice: Comparison of stable and chemically labile linker systems. Bioconj. Chem., 1998, 9, 87-93.
153. Norman, T.J.; Parker, D.; Royle, L.; Harrison, A.; Antoniw, P.; King, D.J. Improved tumor targeting with recombinant antibodymacrocycle conjugates. J. Chem. Soc. Chem. Commun., 1995, 1877-1878.
154. Wilbur, D.S. Radiohalogenation of proteins: An overview of radionuclides, labeling methods, and reagents for conjugate labeling. Bioconj. Chem., 1992, 3, 433-70.
155. Aslam, M.; Dent, A., Bioconjugation. Protein coupling techniques for the biomedical sciences. Grove's Dictionaries Inc.: New York, 1998, p 833.
156. nd ed.; Academic Press: Amsterdam, 2008.
157. Kline, S.J.; Betebenner, D.A.; Johnson, D.K. Carboxymethylsubstituted bifunctional chelators: Preparation of aryl isothiocyanate derivatives of 3-(carboxymethyl)-3-azapentanedioic acid, 3,12-bis(carboxymethyl)-6,9-dioxa-3,12-diazatetra-decanedioic acid, and 1,4,7,10-tetraazacyclo-dodecane-N, N', N", N"'-tetraacetic acid for use as protein labels. Bioconj. Chem., 1991, 2, 26-31.
158. Kruper, W.J. Process for preparing mono-N-alkylated polyazamacrocycles. US Patent 5,064,956, 1991.
159. Chappell, L.L.; Rogers, B.E.; Khazaeli, M.B.; Mayo, M.S.; Buchsbaum, D.J.; Brechbiel, M.W. Improved synthesis of the bifunctional chelating agent 1,4,7,10-tetraaza-N-(1-carboxy-3-(4-nitrophenyl)propyl)-N ', N ", N "'-tris(acetic acid)-cyclododecane (PA-DOTA). Bioorg. Med. Chem., 1999, 7, 2313-2320.
160. Stimmel, J.B.; Stockstill, M.E.; Kull, F.C. Yttrium-90 chelation properties of tetraazatetraacetic acid macrocycles, diethylenetriaminepentaacetic acid analogues, and a novel terpyridine acyclic chelator. Bioconj. Chem., 1995, 5, 219-225.
161. 177Lu: In vivo comparison of macrocyclic and acyclic ligands. Nucl. Med. Biol., 2010, 37, 741-50.
162. Chappell, L.L.; Ma, D.; Milenic, D.E.; Garmestani, K.; Venditto, V.; Beitzel, M.P.; Brechbiel, M.W. Synthesis and evaluation of novel bifunctional chelating agents based on 1,4,7,10-tetraazacyclo-dodecane-N, N', N", N"'-tetraacetic acid for radiolabeling proteins. Nucl. Med. Bio., 2003, 30, 581-595.
163. Ranganathan, R.S.; Pillai, R.K.; Raju, N.; Fan, H.; Nguyen, H.; Tweedle, M.F.; Desreux, J.F.; Jacques, V. Polymethylated DOTA ligands. 1. Synthesis of rigidified ligands and studies on the effects of alkyl substitution on acid-base properties and conformational mobility. Inorg. Chem., 2002, 41, 6846-55.
164. Chong, H.S.; Lim, S.; Baidoo, K.E.; Milenic, D.E.; Ma, X.; Jia, F.; Song, H.A.; Brechbiel, M.W.; Lewis, M.R. Synthesis and biological evaluation of a novel decadentate ligand DEPA. Bioorg. Med. Chem. Lett., 2008, 18, 5792-5795.
165. Broan, C.F.; Cox, J.P.L.; Craig, A.S.; Kataky, R.; Parker, D.; Harrison, A.; Randall, A.M.; Ferguson, G. Structure and solution stability of indium and gallium complexes of 1,4,7-triazacyclononane-triacetate and of yttrium complexes of 1,4,7,10-tetraazacyclododecanetetraacetate and related ligands: Kinetically stable complexes for use in imaging and radioimmunotherapy, xray molecular structure of the indium and gallium complexes of 1,4,7-triazacyclononane-1,4,7-triacetic acid. J. Chem. Soc. Perkin Trans. 2, 1991, 87-99.
166. 64Cu-BAT-2IT-1A3. Cancer Bioth. Radiopharm., 2001, 16, 483-494.
167. Ruser, G.; Ritter, W.; Maecke, H.R. Synthesis and evaluation of two new bifunctional carboxy-methylated tetraazamacrocyclic chelating agents for protein labeling with indium-111. Bioconj. Chem., 1990, 1, 345-349.
168. 88YIII complexes. J. Org. Chem., 1993, 58, 1955-1958.
169. Takenouchi, K.; Tabe, M.; Watanabe, K.; Hazato, A.; Kato, Y.; Shionaya, M.; Koike, T.; Kimura, E. Novel pendant-type macrocyclic bifunctional chelating agents: (carboxymethyl)amino deriva-tives of 2-(4-nitrobenzyl)-1,4,7,10-tetraazacyclo-dodecane-N, N', N", N"'-tetraacetic acid and their complex formation with yttrium (III). J. Org. Chem., 1993, 58, 6895-6899.
170. Kodama, M.; Koike, T.; Mahatma, A.B.; Kimura, E. Thermodynamic and kinetic studies of lanthanide complexes of 1,4,7,10,13-pentaaza-cyclopentadecane-N, Ń, Ń́, Ń́́, Ń́́́-pentaacetic acid and 1,4,7,10,13,16-hexaazacyclooctadecane-N, Ń, Ń́, Ń́́, Ń́́́, Ń́́́́-hexaacetic acid. Inorg. Chem., 1991, 30, 1270-1273.
171. 225Ac radioimmunotherapy applications. Bioconj. Chem., 2000, 11, 510-519.
172. Studer, M.; Meares, C.F. Synthesis of novel 1,4,7-triazacyclononane-N, N', N"-triacetic acid deriva-tives suitable for protein labeling. Bioconj. Chem., 1992, 3, 337-341.
173. 71Ga NMR, and crystal structure of a neutral gallium(III) complex of 1,4,7-triazacyclo-nonanetriacetate: A potential radiopharmaceutical? J. Chem. Soc. Chem. Commun., 1989, 1793-1794.
174. 68Ga-labeled C(RGDyk)-isothiocyanatobenzyl-1,4,7-triazacyclononane-1,4,7-triacetic acid and feasibility studies in mice. J. Nucl. Med., 2008, 49, 830-836.
175. 2] targeting vector for positron-emission tomography imaging of gastrinreleasing peptide receptor-expressing tissues. Proc. Natl. Acad. Sci. USA, 2007, 104, 12462-12467.
176. 4 linkers: Promising agents for tumor integrin alphavbeta3 PET imaging. Eur. J. Nucl. Med. Mol. Imaging, 2009, 36, 947-957.
177. Craig, A.S.; Helps, I.M.; Jankowski, K.J.; Parker, D.; Beeley, N.R.A.; Boyce, B.A.; Eaton, M.A.W.; Millican, A.T.; Millar, K.; Phipps, A.; Rhind, S.K.; Harrison, A.; Walker, C. Towards tumor imaging with indium-111 labelled macrocycle-antibody conjugates. J. Chem. Soc. Chem. Commun., 1989, 794-796.
178. Chong, H.S.; Garmestani, K.; Ma, D.; Milenic, D.E.; Overstreet, T.; Brechbiel, M.W. Synthesis and biological evaluation of novel macrocyclic ligands with pendent donor groups as potential yttrium chelators for radioimmunotherapy with improved complex formation kinetics. J. Med. Chem., 2002, 45, 3458-64.
179. Chong, H.S.; Ma, X.; Le, T.; Kwamena, B.; Milenic, D.E.; Brady, E.D.; Song, H.A.; Brechbiel, M.W. Rational design and generation of a bimodal bifunctional ligand for antibody-targeted radiation cancer therapy. J. Med. Chem., 2008, 51, 118-125.
180. Chong, H.S.; Song, H.A.; Ma, X.; Milenic, D.E.; Brady, E.D.; Lim, S.; Lee, H.; Baidoo, K.; Cheng, D.; Brechbiel, M.W. Novel bimodal bifunctional ligands for radioimmunotherapy and targeted MRI. Bioconj. Chem., 2008, 19, 1439-47.
181. Stetter, H.; Frank, W.; Mertens, R. Darstellung und komplexbildung von polyazacycloalkan-N-essigsauren. Tertrahedron, 1981, 37, 767-772.
182. Siaugue, J.-M.; Segat-Dioury, F.; Favre-Reguillon, A.; Madic, C.; Foos, J.; Guy, A. An efficient synthesis of pyridine containing triaza-macrocyclic triacetate ligand and luminescence properties of its europium(III) complex. Tetrahedron Lett., 2000, 41, 7443-7446.
183. Kim, W.D.; Hrncir, D.C.; Kiefer, G.E.; Sherry, A.D. Synthesis, crystal structure, and potentiometry of pyridine-containing tetraaza macrocycle ligands with acetate pendant arms. Inorg. Chem., 1995, 34, 2225-2232.
184. Kim, W.D.; Kiefer, G.E.; Maton, F.; McMillan, K.; Muller, R.N.; Sherry, A.D. Relaxometry, luminescence measurements, electrophoresis, and animal biodistribution of lanthanide(III) complexes of some polyaza macrocyclic acetates containing pyridine. Inorg. Chem., 1995, 34, 2225-2232.
185. Tircso, G.; Kovacs, Z.; Sherry, A.D. Equilibrium and formation/dissociation kinetics of some Ln(III)PCTA complexes. Inorg Chem, 2006, 45, 9269-80.
186. Ferreira, C.L.; Yapp, D.T.; Lamsa, E.; Gleave, M.; Bensimon, C.; Jurek, P.; Kiefer, G.E. Evaluation of novel bifunctional chelates for the development of Cu-64-based radiopharmaceuticals. Nucl. Med. Biol., 2008, 35, 875-82.
187. 64Cu antibody imaging. Eur. J. Nucl. Med. Mol. Imaging, 2010, 37, 2117-2126.
188. Tircso, G.; Benyo, E.T.; Suh, E.H.; Jurek, P.; Kiefer, G.E.; Sherry, A.D.; Kovacs, Z. (S)-5-(p-nitrobenzyl)-PCTA, a promising bifunctional ligand with advantageous metal ion complexation kinetics. Bioconj. Chem., 2009, 20, 565-575.
189. +. Dalton Trans., 2005, 3204-3212.
190. Corneillie, T.M.; Whetstone, P.A.; Fisher, A.J.; Meares, C.F. A rare earth-DOTA-binding antibody: Probe properties and binding affinity across the lanthanide series. J. Am. Chem. Soc., 2003, 125, 3436-3437.
191. Corneillie, T.M.; Whetstone, P.A.; Meares, C.F. Irreversibly binding anti-metal chelate antibodies: Artificial receptors for pretargeting. J. Inorg. Biochem., 2006, 100, 882-90.
192. Butlin, N.G.; Meares, C.F. Antibodies with infinite affinity: Origins and applications. Acc. Chem. Res., 2006, 39, 780-787.
193. 212Bi) therapy. Cancer Res., 1993, 53, 5683-5689.
194. Nayak, T.; Norenberg, J.; Anderson, T.; Atcher, R. A comparison of high-versus low-linear energy transfer somatostatin receptor targeted radionuclide therapy in vitro. Cancer Biother. Radiopharm., 2005, 20 (1), 52-7.
195. 177Lu in human pancreatic adenocarcinoma cells. Nucl. Med. Biol., 2007, 34, 185-93.
196. 3]octreotide peptide receptor radionuclide therapy of pancreatic tumors in a preclinical animal model. Clin. Cancer Res., 2006, 12, 897-903.
197. 213Bi-DOTA-[Thi8, Met(O2)11]-substance P: A pilot trial. Eur. J. Nucl. Med. Mol. Imaging, 2010, 37, 1335-1344.
198. Zhang, M.; Yao, Z.; Garmestani, K.; Axworthy, D.B.; Zhang, Z.; Mallett, R.W.; Theodore, L.J.; Goldman, C.K.; Brechbiel, M.W.; Carrasquillo, J.A.; Waldmann, T.A. Pretargeting radioimmuno therapy of a murine model of adult T-cell leukemia with the t-emitting radionuclide, bismuth 213. Blood, 2002, 100, 208-216.
199. Axworthy, D.B.; Reno, J.M.; Hylarides, M.D.; Mallett, R.W.; Theodore, L.J.; Gustavson, L.M.; Su, F.; Hobson, L.J.; Beaumier, P.L.; Fritzberg, A.R. Cure of human carcinoma xenografts by a single dose of pretargeted yttrium-90 with negligible toxicity. Proc. Natl. Acad. Sci. USA., 2000, 97, 1802-7.
200. 212Bi-DOTMP: An alpha particle emitting bone-seeking agent for targeted radiotherapy. Nucl. Med. Biol., 1997, 24, 231-237.
201. 212Bisynthesis and biodistribution of a novel bone seeking alphaemitting radiopharmaceutical. J. Label. Compd. Radiopharm., 1994, 34, 717-734.
202. Kumar, K.; Magerstädt, M.; Gansow, O.A. Lead(II) and bismuth(III) complexes of the polyazacycloalkane-N-acetic acids NOTA, DOTA, and TETA. J. Chem. Soc., Chem. Commun., 1989, 3, 145-146.
203. 3+ complexes of hexalactam macrocycle. Nucl. Med. Biol., 1990, 17, 409-412.
204. Halime, Z.; Lachkar, M.; Boitrel, B. Coordination of bismuth and lead in porphyrins: Towards an in-situ generator for alpharadiotherapy? Biochimie, 2009, 91, 1318-20.
205. 2-. Radiochimica Acta, 1993, 60, 1-10.
206. Wrasidlo, W.; Mysels, K.J. Generation of lead-212 and radioimmunoconjugates for use in cancer therapy and the 'emanating power' of stearates. Colloids Surf., A, 2001, 186, 123-128.
207. 203Pb labeled monoclonal antibodies. Inorganica Chimica Acta, 1995, 239, 43-51.
208. 212Pb-labeled monoclonal antibody in the treatment of murine erythroleukemia. Int. J. Appl. Rad. Oncol. Biol. Phys., 1996, 34, 609-616.
209. Horak, E.; Hartmann, F.; Garmestani, K.; Wu, C.; Brechbiel, M.; Gansow, O.A.; Landolfi, N.F.; Waldmann, T.A. Radioimmunotherapy targeting of HER2/neu oncoprotein on ovarian tumor using lead-212-DOTA-AE1. J. Nuc. Med, 1997, 38, 1944-1950.
210. Carlton, L.; Hancock, R.D.; Maumela, H.; Wainright, K.P. Stability enhancement of heavy-metal-macrocycle complexes via pendant amide coordination. J. Chem. Soc. Chem. Commun., 1994, 1007-1008.
211. Maumela, H.; Hancock, R.D.; Carlton, L.; Reibenspies, J.H.; Wainwright, K.P. The amide oxygen as a donor group. Metal ion complexing properties of tetra-N-acetamide substituted cyclen: A crystallographic, nmr, molecular mechanics, and thermodynamic study. J. Am. Chem. Soc., 1995, 117, 6698-6707.
212. Hollemans, M.; Elferink, R.O.; De Groot, P.G.; Strijland, A.; Tager, J.M. Accumulation of weak bases in relation to intralysosomal pH in cultured human skin fibroblasts. Biochim. Biophys. Acta, 1981, 643, 140-51.
213. Ohkuma, S.; Poole, B. Fluorescence probe measurement of the intralysosomal pH in living cells and the perturbation of pH by various agents. Proc. Natl. Acad. Sci. USA, 1978, 75, 3327-31.
214. De Duve, C.; De Barsy, T.; Polle, B.; Trouet, A.; Tulkens, P.; Van Hoof, F. Lysosomotropic agents. Biochem. Pharm., 1974, 23, 2495-2531.
215. Milenic, D.E.; Garmestani, K.; Brady, E.D.; Albert, P.S.; Abdulla, A.; Flynn, J.; Brechbiel, M.W. Potentiation of high-LET radiation by gemcitabine: Targeting HER2 with trastuzumab to treat disseminated peritoneal disease. Clin. Cancer Res., 2007, 13, 1926-35.
216. Miao, Y.; Hylarides, M.; Fisher, D.R.; Shelton, T.; Moore, H.; Wester, D.W.; Fritzberg, A.R.; Winkelmann, C.T.; Hoffman, T.; Quinn, T.P. Melanoma therapy via peptide-targeted {alpha}-radiation. Clin. Cancer Res., 2005, 11, 5616-21.
217. 212Bi generator. Nucl. Med. Biol., 2005, 32, 741-7.
218. McDowell, W.J.; Case, G.N.; Aldrup, D.W. Investigations of ionsize-selective synergism in solvent extraction. Separation Sci. Technol., 1988, 23, 1251-1268.
219. Chen, X. Rational design of bifunctional chelating agents for alpha-emitters radium-223 and actinium-225 in radioimmunotherapy of cancer. PhD Thesis, University of Idaho: Moscow, 1999.
220. th Proceedings of the ACS National Meeting, Anaheim, CA, March 21-25; American Chemical Society, 1999.
221. Chen, X.; Ji, M.; Fisher, D.R.; Wai, C.M. Carboxylate-derived calixarenes with high selectivity for actinium-225. Chem. Commun., 1998, 377-378.
222. Chen, X.Y.; Ji, M.; Fisher, D.R.; Wai, C.M. Monofunctionalization of calix[4]arene tetra-carboxylic acid at the upper rim with isothiocyanate group: First bifunctional chelating agent for alphaemitter Ac-225. Synlett, 1999, 11, 1784-1786.
223. Grote Gansey, M.H.; Verboom, W.; van Veggel, F.C.J.M.; Vetrogon, V.; Arnaud-Neu, F.; Schwing-Weill, M.-J.; Reinhoudt, D.N. Model studies toward trivalent cation binding by approximately functionalized calix[4]arenes. J. Chem. Soc. Perkin Trans. II, 1998, 2351-2360.
224. 3+ chelators. Bioconj. Chem., 1999, 10, 613-23.
225. Deal, K.A.; Davis, I.A.; Mirzadeh, S.; Kennel, S.J.; Brechbiel, M.W. Improved in vivo stability of actinium-225 macrocyclic complexes. J. Med. Chem., 1999, 42, 2988-2992.
226. 225Ac for vascular targeted radioimmunotherapy of lung tumors. Cancer Biother. Radiopharm., 2000, 15, 235-244.
227. Kennel, S.J.; Brechbiel, M.W.; Milenic, D.E.; Schlom, J.; Mirzadeh, S. Actinium-225 conjugates of MAb CC49 and humanized DCH2CC49. Cancer Biother. Radiopharm., 2002, 17 (2), 219-231.
228. McDevitt, M.R.; Ma, D.; Lai, L.T.; Simon, J.; Borchardt, P.; Frank, R.K.; Wu, K.; Pellegrini, V.; Curcio, M.J.; Miederer, M.; Bander, N.H.; Scheinberg, D.A. Tumor therapy with targeted atomic nanogenerators. Science (Washington, DC, U. S.), 2001, 294 (5546), 1537-1540.
229. 225Ac radioimmunopharmaceuticals. Appl. Radiat. Isot., 2002, 57, 841-847.
230. Borchardt, P.E.; Yuan, R.R.; Miederer, M.; McDevitt, M.R.; Scheinberg, D.A. Targeted actinium-225 in vivo generators for therapy of ovarian cancer. Cancer Res., 2003, 63, 5084-90.
231. 225Ac-Hum195, in nonhuman primates. J. Nucl. Med., 2004, 45, 129-137.
232. Ballangrud, A.M.; Yang, W.H.; Palm, S.; Enmon, R.; Borchardt, P.E.; Pellegrini, V.A.; McDevitt, M.R.; Scheinberg, D.A.; Sgouros, G. Alpha-particle emitting atomic generator (actinium-225)-labeled trastuzumab (herceptin) targeting of breast cancer spheroids: Efficacy versus HER2/neu expression. Clin. Cancer Res., 2004, 10, 4489-4497.
233. 90Y. Cancer Res., 2009, 69, 8941-8.
234. Antczak, C.; Jaggi, J.S.; LeFave, C.V.; Curcio, M.J.; McDevitt, M.R.; Scheinberg, D.A. Influence of the linker on the biodistribution and catabolism of actinium-225 self-immolative tumor-targeted isotope generators. Bioconj. Chem, 2006, 17, 1551-60.
235. Yuan, R.R.; Wong, P.; McDevitt, M.R.; Doubrovina, E.; Leiner, I.; Bornmann, W.; O'Reilly, R.; Pamer, E.G.; Scheinberg, D.A. Targeted deletion of T-cell clones using alpha-emitting suicide MHC tetramers. Blood, 2004, 104, 2397-2402.
236. 227Thlabeled antibodies. Curr. Radiopharm., 2008, 1, 209-214.
237. Washiyama, K.; Amano, R.; Sasaki, J.; Kinuya, S.; Tonami, N.; Shiokawa, Y.; Mitsugashira, T. 227Th-EDTMP: A potential therapeutic agent for bone metastasis. Nucl. Med. Biol., 2004, 31, 901-908.
238. Henriksen, G.; Bruland, O.S.; Larsen, R.H. Thorium and actinium polyphosphonate compounds as bone-seeking alpha particleemitting agents. Anticancer Res., 2004, 24, 101-5.
239. 227Th-p-benzyl-DOTA-rituximab for low-dose rate alpha-particle radioimmunotherapy. Nucl. Med. Biol., 2006, 33, 271-9.
240. Larsen, R.H.; Borrebaek, J.; Dahle, J.; Melhus, K.B.; Krogh, C.; Valan, M.H.; Bruland, O.S. Preparation of Th227-labeled radioimmuno-conjugates, assessment of serum stability and antigen binding ability. Cancer Biother. Radiopharm., 2007, 22, 431-7.
241. Dahle, J.; Borrebaek, J.; Jonasdottir, T.J.; Hjelmerud, A.K.; Melhus, K.B.; Bruland, O.S.; Press, O.W.; Larsen, R.H. Targeted cancer therapy with a novel low-dose rate alpha-emitting radioimmunoconjugate. Blood, 2007, 110, 2049-2056.
242. Coenen, H.H.; Moerlein, S.M.; Stöcklin, G. No-carrier-added radiohalogenation methods with heavy halogens. Radiochimica Acta, 1983, 34, 47-68.
243. Brown, I. Astatine: Its organonuclear chemistry and biomedical applications. Adv. Org. Chem., 1987, 31, 43-88.
244. Berei, K.; Vasáros, L., Recent advances in the organic chemistry of astatine. In Supplement 2: The chemistry of halides, pseudo-halides and azides., Patai, S.; Rappoport, Z., Eds. John Wiley & Sons Ltd: New York, 1995, pp 787-819.
245. th ed.; Springer-Verlag: Berlin, 1985.
246. Corson, D.R.; Mackenzie, K.R.; Segre, E. Artificially radioactive element 85. Phys. Rev., 1940, 58, 672-678.
247. Johnson, G.L.; Leininger, R.F.; Segre, E. Chemical properties of astatine. I. J. Chem. Phys., 1949, 17, 1-10.
248. Hamilton, J.G.; Soley, M.H. A comparison of the metabolism of iodine and of element 85 (eka-iodine). Proc. Natl. Acad. Sci, USA, 1940, 26, 483-489.
249. Milesz, S.; Jovchev, M.; Schumann, D.; Khalkin, V.A.; Milanov, M. The EDTA complexes of astatine. J. Radioanal. Nucl. Chem., Letters 1988, 127, 193-198.
250. Milesz, S.; Norseev, Y.V.; Szucs, Z.; Vasaros, L. Characterization of DTPA complexes and conjugated antibodies of astatine. J. Radioanal. Nucl. Chem. Lett., 1989, 137, 365-372.
251. Ning, L.; Jiannan, J.; Shangwu, M.; Hengliu, C.; Yanping, Y. Preparation and preliminary evaluation of astatine-211 labeled IgG via DTPA anhydride. J. Radioanal. Nucl. Chem., 1998, 227, 187-190.
252. 211At-calix[4]arene complex. J. Label. Compd. Radiopharm., 2000, 43, 1219-1225.
253. 211At complexes as possible precursors for astatine radiopharm-aceuticals. J. Label. Compd. Radiopharm., 2007, 50 (S1), S32.
254. 211At complexes as potential precursors for astatine radiopharmaceuticals. Part I: Synthesis. Bioconj. Chem., 2008, 19, 958-65.
255. Aaij, C.; Tschroots, W.R.J.M.; Lindner, L.; Feltkamp, T.E.W. The preparation of astatine labelled proteins. Int. J. Appl. Rad. Isot., 1975, 26, 25-30.
256. Vaughan, A.T.M.; Fremlin, J.H. The preparation of astatine labelled proteins using an electrophilic reaction. Int. J. Nucl. Med. Biol., 1978, 5, 229-230.
257. Zalutsky, M.R.; Narula, A.S. Astatination of proteins using an Nsuccinimidyl tri-n-butylstannyl benzoate intermediate. Appl. Radiat. Isot., 1988, 39, 227-232.
258. 2. Nucl. Med. Biol., 1993, 20, 917-927.
259. 211At labeling of humanized anti-tac. Nucl. Med. Biol., 2001, 28, 845-856.
260. Persson, M.I.; Gedda, L.; Jensen, H.J.; Lundqvist, H.; Malmstrom, P.U.; Tolmachev, V. Astatinated trastuzumab, a putative agent for radionuclide immunotherapy of ErbB2-expressing tumours. Oncol. Rep., 2006, 15, 673-80.
261. Wilbur, D.S.; Chyan, M.K.; Hamlin, D.K.; Vessella, R.L.; Wedge, T.J.; Hawthorne, M.F. Reagents for astatination of biomolecules. 2. Conjugation of anionic boron cage pendant groups to a protein provides a method for direct labeling that is stable to in vivo deastatination. Bioconj. Chem., 2007, 18, 1226-40.
262. 211At-astato-imidazoles. Int. J. Appl. Rad. Isot., 1980, 31, 275-278.
263. Visser, G.W.M.; Diemer, E.L.; Vos, C.M.; Kaspersen, F.M. The biological behaviour of some organic astatine compounds in rats. Int. J. Appl. Rad. Isopt., 1981, 32, 913-917.
264. 211At]astato-N-piperidinoethyl benzamide. Nucl. Med. Biol., 1995, 22, 467-473.
265. Foulon, C.F.; Alston, K.L.; Zalutsky, M.R. Synthesis and preliminary biological evaluation of (3-iodobenzoyl)norbiotinamide and (5-iodo-3-pyridinyl)carbonyl)norbiotinamide: Two radio-iodinated biotin conjugates with improved stability. Bioconj. Chem., 1997, 8, 179-186.
266. Kerr, J.A. Strengths of chemical bonds. CRC Handbook of Chemistry and Physics, 1993, 9-144 to 9-145.
267. Grimes, R.N., Carboranes. Academic Press: New York, 1970.
268. 12 and their derivatives. Chem. Rev., 1992, 92, 209-223.
269. 12-2. Inorg. Chem., 1964, 3, 159-167.
270. Olsen, F.P.; Hawthorne, M.F. Halodicarba-undecaborate(II) ions. Inorg. Chem., 1965, 4, 1839-1840.
271. 2-. Angew. Chem. Int. Ed., 1977, 16, 173-174.
272. Sieckhaus, J.F.; Semenuk, N.S.; Knowles, T.A.; Schroeder, H. Icosahedral carboranes. XIII. Halogenation of p-carborane. Inorg. Chem., 1969, 8, 2452-2457.
273. Hawthorne, M.F. The role of chemistry in the development of boron neutron capture therapy of cancer. Angew. Chem. Int. Ed., 1993, 32, 950-984.
274. Soloway, A.H.; Tjarks, W.; Barnum, B.A.; Rong, F.G.; Barth, R.F.; Codogni, I.M.; Wilson, J.G. The chemistry of neutron capture therapy. Chem. Rev., 1998, 98, 1515-1562.
275. Srivastava, R.R.; Hamlin, D.K.; Wilbur, D.S. Synthesis of highly iodinated icosahedral mono-and dicarbon carboranes. J. Org. Chem., 1996, 61, 9041-9044.
276. Wilbur, D.S.; Hamlin, D.K.; Buhler, K.R.; Srivastava, R.R.; Stray, J.E.; Daniel, J.; Vessella, R.L. Comparison of in vivo distributions of simple radioiodinated borane and carborane cage molecules. Quart. Rev. Nucl. Med., 1995, 39, 51-52.
277. Wilbur, D.S.; Hamlin, D.K.; Srivastava, R.R.; Chyan, M.K. Synthesis, radioiodination, and biodistribution of some nido-and closo-monocarbon carborane derivatives. Nucl. Med. Biol., 2004, 31, 523-30.
278. Ghirami, S.; Malmquist, J.; Lundquist, H.; Tolmachev, V.; Sjöberg, S. Synthesis and radioiodination of 7-(3́-ammoniopropyl)-7,8-dicarba-nido-undecaborate(-1), (ANC). J. Labl. Compds. Radiopharm., 2004, 47, 557-569.
279. Wilbur, D.S.; Chyan, M.K.; Hamlin, D.K.; Kegley, B.B.; Risler, R.; Pathare, P.M.; Quinn, J.; Vessella, R.L.; Foulon, C.; Zalutsky, M.; Wedge, T.J.; Hawthorne, M.F. Reagents for astatination of biomolecules: Comparison of the in vivo distribution and stability of some radioiodinated/astatinated benzamidyl and nido-carboranyl compounds. Bioconj. Chem, 2004, 15, 203-23.
280. Wilbur, D.S.; Chyan, M.K.; Hamlin, D.K.; Perry, M.A. Reagents for astatination of biomolecules. 3. Comparison of closodecaborate(2-) and closo-dodecaborate(2-) moieties as reactive groups for labeling with astatine-211. Bioconj. Chem., 2009, 20, 591-602.
281. Wilbur, D.S.; Chyan, M.K.; Hamlin, D.K.; Perry, M.A. Preparation and in vivo evaluation of radioiodinated closo-decaborate(2-) derivatives to identify structural components that provide low retention in tissues. Nucl. Med. Biol., 2010, 37, 167-78.
282. 11]. Inorg. Chem., 1985, 24, 1911-1916.
283. Varadarajan, A.; Sharkey, R.M.; Goldenberg, D.M.; Hawthorne, M.F. Conjugation of phenyl isothiocyanate derivatives of carborane to antitumor antibody and in vivo lacalization of conjugates in nude mice. Bioconj. Chem., 1991, 2, 102-110.
284. Paxton, R.J.; Beatty, B.G.; Varadarajan, A.; Hawthorne, M.F. Carboranyl peptide-antibody conjugates for neutron-capture therapy: Preparation, characterization, and in vivo evaluation. Biocon. Chem., 1992, 3, 241-247.
285. 76Br]undecahydro-bromo-7,8-dicarba-nido-undecaborate(1-) ion. Nucl. Med. Biol., 2004, 31, 425-433.
286. Wilbur, D.S.; Hamlin, D.K.; Pathare, P.M.; Kegley, B.B. Synthesis of a nido-carborane derivative for use as a protein conjugate for direct
287. Gedda, L.; Olsson, P.; Pontén, J.; Carlsson, J. Development and in vitro studies of epidermal growth factor-dextran conjugates for boron neutron capture therapy. Bioconj. Chem., 1996, 7, 584-591.
288. Tolmachev, V.; Koziorowski, J.; Sivaev, I.; Lundqvist, H.; Carlsson, J.; Orlova, A.; Gedda, L.; Olsson, P.; Sjoberg, S.; Sundin, A. closo-Dodecaborate(2-) as a linker for iodination of macromolecules. Aspects on conjugation chemistry and biodistribution. Bioconj. Chem., 1999, 10, 338-45.
289. Orlova, A.; Lebeda, O.; Tolmachev, V.; Sjoberg, S.; Carlsson, J.; Lundqvist, H. Astatination of closo-dodecaborate(2-) anion. J. Label. Compd. Radiopharm., 1999, 42, S735-S737.
290. Nestor, M.; Persson, M.; Cheng, J.; Tolmachev, V.; Van Dongen, G.; Anniko, M.; Kairemo, K. Biodistribution of the chimeric monoclonal antibody U36 radioiodinated with a closododecaborate-containing linker. Comparison with other radioiodination methods. Bioconj. Chem., 2003, 14, 805-810.
291. Persson, M.; Sivaev, I.; Winberg, K.J.; Gedda, L.; Malmstrom, P.U.; Tolmachev, V. In vitro evaluation of two polyhedral boron anion derivatives as linkers for attachment of radioiodine to the anti-HER2 monoclonal antibody trastuzumab. Cancer Biother. Radiopharm., 2007, 22, 585-96.
292. 125I-labeled closo-decaborate(2-) conjugates of Fab́ as a means of decreasing kidney retention. Bioconj. Chem., 2011, in press.
293. 212Pb@C(60) and its water-soluble derivatives: Synthesis, stability, and suitability for radioimmunotherapy. J. Am. Chem. Soc., 2007, 129, 5131-8.
294. th American Chemical Society meeting, Boston, MA, August 2010.
295. 211AtCl@us-tube nanocapsules: A new concept in radiotherapeuticagent design. Small, 2007, 3, 1496-1499.
296. Fitzsimmons, J.; Atcher, R. Synthesis and evalation of a watersoluble polymer to reduce Ac-225 daughter migration. J. Label. Compds. Radiopharm., 2007, 50, 147-153.
297. th American Chemical Society meeting, Boston, MA, August 2010.
298. Senior, J.; Delgado, C.; Fisher, D.; Tilcock, C.; Gregoriadis, G. Influence of surface hydrophilicity of liposomes on their interaction with plasma protein and clearance from the circulation: Studies with poly(ethyleneglycol)-coated vesicles. Biochim. Biophy. s Acta, 1991, 1062, 77-82.
299. 212Bi. Radiochimica Acta, 2003, 91, 109-113.
300. Henriksen, G.; Schoultz, B.W.; Michaelsen, T.E.; Bruland, O.S.; Larsen, R.H. Sterically stabilized liposomes as a carrier for alphaemitting radium and actinium radionuclides. Nucl. Med. Biol., 2004, 31, 441-9.
301. Sofou, S.; Thomas, J.L.; Lin, H.Y.; McDevitt, M.R.; Scheinberg, D.A.; Sgouros, G. Engineered liposomes for potential alphaparticle therapy of metastatic cancer. J. Nucl. Med., 2004, 45, 253-60.
302. Sofou, S.; Kappel, B.J.; Jaggi, J.S.; McDevitt, M.R.; Scheinberg, D.A.; Sgouros, G. Enhanced retention of the alpha-particleemitting daughters of actinium-225 by liposome carriers. Bioconj. Chem., 2007, 18, 2061-7.
303. 225Ac in rigid liposomes for potential targeted therapy of micrometastases. Bioconj. Chem., 2008, 19, 1274-82.
304. Hall, E.J.; Giaccia, A.J., Repair of radiation damage and the dose rate effect. In Radiobiology for the radiologist., Lippencott Williams & Wilkins: Philadelphia, 2006, pp 60-84.
305. Carlsson, J.; Eriksson, V.; Stenerlow, B.; Lundqvist, H. Requirements regarding dose rate and exposure time for killing of tumour cells in beta particle radionuclide therapy. Eur. J Nucl. Med. Mol. Imaging, 2006, 33 (10), 1185-1195.
306. Hall, E.J.; Giaccia, A.J., Oxygen effect and reoxygenation. In Radiobiology for the radiologist., Sixth Edition ed.; Lippincott Williams & Wilkins: Philadelpha, 2006, pp 85-105.
307. Bethge, W.A.; Wilbur, D.S.; Sandmaier, B.M. Radioimmunotherapy as non-myeloablative conditioning for allogeneic marrow transplantation. Leuk. Lymphoma, 2006, 47, 1205-14.
308. Fritzberg, A.R.; Beaumier, P.L.; Bottino, B.J.; Reno, J.M. Approaches to improved antibody-and peptide-mediated targeting for imaging and therapy of cancer. J. Controlled Release, 1994, 28, 167-173.
309. 131-labeled proteins in solution. Ann. N. Y. Acad. Sci., 1957, 70, 56-68.
310. Garrison, W.M. Reaction mechanisms in the radiolysis of peptides, polypeptides, and proteins. Chem. Rev., 1985, 87, 381-398.
311. th Ed.; Lippincott Williams & Wilkins: Philadelphia, 2006, pp. 106-116.
312. Salako, Q.A.; O'Donnell, R.T.; DeNardo, S.J. Effects of radiolysis on yttrium-90-labeled Lym-1 antibody preparations. J. Nucl. Med., 1998, 39, 667-70.
313. 188Re labelled compounds. Appl. Radiat. Isot., 2003, 58, 353-359.
314. Halliwell, B. Albumin-an important extracellular antioxidant? Biochem. Pharm., 1988, 37, 569-571.
315. 90Y-labeled DOTAbiomolecule conjugates using gentisic acid and ascorbic acid. Bioconj. Chem., 2001, 12, 554-558.
316. Liu, S.; Ellars, C.E.; Edwards, D.S. Ascorbic acid used as a buffer agent and radiolytic stabilizer for metalloradiopharmaceuticals. Bioconj. Chem., 2003, 14, 1052-1056.
317. Wahl, R.L.; Wissing, J.; del Rosario, R.; Zasadny, K.R. Inhibition of autoradiolysis of radiolabeled monoclonal antibodies by cryopreservation. J. Nucl. Med., 1990, 31, 84-89.
318. Kishore, R.; Eary, J.F.; Krohn, K.A.; Nelp, W.B.; Menard, T.W.; Beaumier, P.L.; Hellström, K.E.; Hellström, I. Autoradiolysis of iodinated monoclonal antibody preparations. Nucl. Med. Biol., 1986, 13, 457-459.
319. Zimmer, A.M.; Kazikiewicz, J.M.; Webber, D.I.; Patel, B.A.; Goldman-Leikin, R.; Radosevich, J.A.; Spies, W.G.; Spies, S.M.; Rosen, S.T. Stability of radioiodinated monoclonal antibodies: In vitro storage and plasma analysis. Int. J. Rad. Appl. Instrum. B, 1989, 16, 691-6.
320. Chakrabarti, M.C.; Le, N.; Paik, C.H.; De Graff, W.G.; Carrasquillo, J.A. Prevention of radiolysis of monoclonal antibody during labeling. J. Nucl. Med., 1996, 37, 1384-1388.
321. 211At alphaparticles. J. Nucl. Med., 2005, 46, 700-6.
322. 211At-astatobenzoate synthesis. J. Nucl. Med., 2005, 46 (8), 1393-400.
323. 211At. J. Nucl. Med., 2007, 48, 1190-6.
324. 68Ga PET imaging agent elaboration. J. Am. Chem. Soc., 2010, 132, 15726-33.
325. Platas-Iglesias, C.; Mato-Iglesias, M.; Djanashvili, K.; Muller, R.N.; Elst, L.V.; Peters, J.A.; de Blas, A.; Rodriguez-Blas, T. Lanthanide chelates containing pyridine units with potential application as contrast agents in magnetic resonance imaging. Chem. Eur. J., 2004, 10, 3579-3590.
326. Saha, A.K.; Kross, K.; Kloszewski, E.D.; Upson, D.A.; Toner, J.L.; Snow, R.A.; Black, C.D.V.; Desai, V.C. Time-resolved fluorescence of a new europium chelate complex: Demonstration of highly sensitive detection of protein and DNA samples. J. Am. Chem. Soc., 1993, 115, 11032-11033.
327. Toner, J.L.; Hilborn, D.A.; Murray, B.J.; Hossain, T.Z. Complexing agents and targeting radioactive immunoreagents useful in therapeutic and diagnostic imaging compositions and methods. U.S. Patent 5,367,080, November 22, 1994.
328. 3+. J. Am. Chem. Soc., 2003, 125, 13324-13325.
329. Johansson, M.K.; Cook, R.M.; Xu, J.; Raymond, K.N. Time gating improves sensitivity in energy transfer assays with terbium chelate/dark quencher oligonucleotide probes. J. Am. Chem. Soc., 2004, 126, 16451-16455.